Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
5 of 5 strong
The short version
The company targets a top-line growth of 25% to 30% annually for FY '27 and the next few years. The company targets a top-line growth of 25% to 30% annually over the next few years.
From Fredun Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets a top-line growth of 25% to 30% annually for FY '27 and the next few years.
- Growth has been steady with a 32% CAGR over the last 19 years, with no degrowth year.
- New age businesses like Pet Care, Mobility, and Nutraceuticals are growing rapidly at 40% to 50% CAGR from smaller bases.
- Vintage pharmaceutical business is growing steadily at 10% to 15%.
- Working capital and cash flows have improved, supporting growth without financial strain.
- EBITDA margins expected to improve over the next 8-9 quarters with a potential spike in profitability as new products saturate demographic reach within 2.5 to 3 years.
- The company aims for sustainable growth, projecting PAT margin around 10% to 12% in the near future.
- Expansion into new demographics, states, and product lines will drive volume and revenue growth.
Profitability & Margins
See what Fredun Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Fredun Pharmaceuticals is actively expanding manufacturing capacity, adding 12 to 13 packing lines by the end of September 2026.
- A new wing is being constructed within their existing plant to further enhance production capabilities.
- The company plans to become one of the top 3-4 manufacturing plants in capacity in the country within the next 2.5 years, leveraging its cluster of 4 plants at one location.
- Facilities are being set up for functional foods and planning to manufacture various wet food products.
- Investment in manufacturing infrastructure took INR400-500 crores over past decades, with ongoing optimization and utilization as a key asset.
- The approach is preemptive, planning for 7-8 years ahead with multiple loan licensing and contract manufacturing agreements established already.
- Emphasis on sustainable growth with continuous capacity augmentation to support new age product lines and organic expansion.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fredun Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Fredun Pharmaceuticals maintains a steady orderbook with 6 to 7 months of orders always in hand.
- Currently, the company has confirmed orders upwards of INR 320 crores to INR 330 crores in hand.
- This robust order pipeline allows the company to give orders ahead to its suppliers, ensuring supply chain stability amid geopolitical changes.
- The buffer stock of raw materials helps absorb cost fluctuations without impacting the bottom line significantly.
- This strong order visibility is considered a significant advantage during volatile market conditions.
Fredun Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹213 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fredun Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Fredun Pharmaceuticals Ltd Q4 FY26 results?
The company targets a top-line growth of 25% to 30% annually for FY '27 and the next few years. The company targets a top-line growth of 25% to 30% annually over the next few years.
What is Fredun Pharmaceuticals Ltd share price analysis?
Fredun Pharmaceuticals Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 57.6 with a market cap of ₹2,560 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fredun Pharmaceuticals Ltd planning capital expenditure?
Fredun Pharmaceuticals is actively expanding manufacturing capacity, adding 12 to 13 packing lines by the end of September 2026.
Keep Fredun Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.